clinical trial · NCT05352893
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Generalized Pustular Psoriasis750 mg Imsidolimab300 mg ImsidolimabPlacebo
brief summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
started
Apr 14, 2022
primary completion
Aug 17, 2023
completion
Aug 17, 2023
last updated
Mar 17, 2026
detailed description
This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP.
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol